Marker Therapeutics reports FY 2023 net loss of $8.2M, down from $29.9M; cash runway into Q4 2025

Marker Therapeutics, Inc.

Net loss narrowed to $8.2M in FY 2023 from $29.9M in FY 2022; R&D spend cut to $10.4M from $12.0M.
Cash and equivalents $15.1M at Dec 31, 2023; company expects funding into Q4 2025 via grant drawdowns.
First lymphoma patient treated with MT-601 achieved sustained complete response >6 months after CAR T relapse.
Completed $19M asset sale to Cell Ready reducing annual overhead ~$11M; secured $2M NIH grant for AML program.
Appointed Juan Vera as CEO/Principal Financial Officer and Monic Stuart as CMO.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Marker Therapeutics, Inc. reported financial results for the fiscal year ended December 31, 2023.

Period: the fiscal year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 25, 2024, Marker Therapeutics, Inc. (the “ Company ”) reported financial results for the fiscal year ended December 31, 2023 and other recent corporate updates.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Marker Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-038533

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.